Back

Application of DOAC Score for the risk-stratification of major bleeding in patients with venous thromboembolism on direct oral anticoagulants: insight from the COMMAND VTE Registry-2

2 September 2024 (09:00 - 09:50)
Organised by: Logo
Congress Presentation Part of: Venous thromboembolism: international perspectives Venous Thromboembolism ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Yuji Nishimoto

Toyonaka Municipal Hospital, Toyonaka (Japan)

9 More presentations in this session

Presentation thumbnail
Types of pulmonary hypertension and prognosis in COVID-19: 18-months analysis of BNP-PL national database.
Doctor A. Mamzer (Lodz, PL)
Abstract Slides Video
Presentation thumbnail
A novel dynamic risk score to predict Clinically Significant Bleeding (CSB) after 3 months of anticoagulation in patients with incident Venous ThromboEmbolism (VTE) and without active cancer.
Doctor A. Cohen (London, GB)
Abstract Slides Video
Presentation thumbnail
Validation of the PESI-Echo score: as a prognostic tool for mortality in acute pulmonary thromboembolism in Mexican population.
Slides Video
Presentation thumbnail
Sex differences in in-hospital management and outcomes of patients with acute pulmonary embolism
Professor C. Becattini (Perugia, IT)
Abstract Slides
Presentation thumbnail
Clinical outcomes of edoxaban treatment without parenteral anticoagulation therapy for acute venous thromboembolism: Insight from the COMMAND VTE Registry-2
Doctor Y. Tsujisaka (Kyoto, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Venous thromboembolism: international perspectives

The Event

Event poster

ESC Congress 2024

2 September 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
An external validation of DOAC score in patients with atrial fibrillation following transcatheter aortic valve replacement
thumbnail
Congress Presentation
Evaluation of the biomarker-based ABC-AF-bleeding risk score and clinically based bleeding scores in 31,605 patients with atrial fibrillation treated with oral anticoagulation
thumbnail
Congress Presentation
A novel dynamic risk score to predict Clinically Significant Bleeding (CSB) after 3 months of anticoagulation in patients with incident Venous ThromboEmbolism (VTE) and without active cancer.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources